A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia
NCT ID: NCT06544499
Last Updated: 2026-02-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE3
69 participants
INTERVENTIONAL
2024-10-18
2028-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Assess the Efficacy and Safety of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP)
NCT04274452
A Study to Assess the Efficacy and Safety of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP).
NCT04188379
A Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age With Chronic Immune Thrombocytopenia (ITP)
NCT07194850
A Study to Evaluate the Efficacy and Safety of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia
NCT04687072
A Long-term Study to Assess the Safety and Efficacy of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP).
NCT04225156
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Efgartigimod IV
Participants receiving efgartigimod IV during the double-blinded treatment period and the open-label treatment period(s)
Efgartigimod IV
Intravenous infusion of efgartigimod
Placebo IV
Participants receiving placebo IV during the double-blinded treatment period and receiving efgartigimod IV during the open-label treatment period(s)
Efgartigimod IV
Intravenous infusion of efgartigimod
Placebo IV
Intravenous infusion of placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Efgartigimod IV
Intravenous infusion of efgartigimod
Placebo IV
Intravenous infusion of placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Has documented baseline mean platelet count of \<30 x 10\^9/L before randomization
* Has a documented duration of primary immune thrombocytopenia (ITP) of more than 12 months on the date of informed consent form (ICF) signature.
* Has documented prior ITP treatment with at least 1 of the following treatments: corticosteroids, intravenous immunoglobulin (IVIg), anti-D immunoglobulin, thrombopoietin receptor agonist (TPO-RAs), or rituximab.
* Has documented insufficient response to a prior ITP treatment (the specific criteria can be found in the protocol).
* Has documented prior response defined as 1 platelet count of ≥50 × 109/L to at least 1 of the following ITP treatments in the 3 years before the date of ICF signature: prednisone, dexamethasone, other or nonspecified corticosteroids, IVIg, or anti-D immunoglobulin
Exclusion Criteria
* Secondary ITP
* Nonimmune thrombocytopenia
* Autoimmune hemolytic anemia
* ITP-associated critical or severe bleeding The complete list of criteria can be found in the protocol.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
argenx
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Mayo Clinic Hospital Scottsdale
Phoenix, Arizona, United States
University of Southern California Norris Comprehensive Cancer Center
Los Angeles, California, United States
Sharp Memorial Hospital
Oceanside, California, United States
University of Colorado Hospital
Aurora, Colorado, United States
Yale University School of Medicine
New Haven, Connecticut, United States
Georgetown University Hospital
Washington D.C., District of Columbia, United States
The University of Chicago Medicine
Chicago, Illinois, United States
The University of Iowa Hospitals & Clinics
Iowa City, Iowa, United States
Tulane University
New Orleans, Louisiana, United States
Henry Ford Health
Detroit, Michigan, United States
University of Minnesota
Minneapolis, Minnesota, United States
Regional Cancer Care Associates, LLC (RCCA)
Little Silver, New Jersey, United States
Clinical Research Alliance Inc.
Westbury, New York, United States
Duke University Medical Center
Durham, North Carolina, United States
University Hospitals Cleveland Medical Center
Cleveland, Ohio, United States
Ohio State University Hospital East
Columbus, Ohio, United States
INTEGRIS Cancer Institute of Oklahoma
Oklahoma City, Oklahoma, United States
Allgemeines Krankenhaus der Stadt Linz
Linz, , Austria
Ordensklinikum Linz GmbH Elisabethinen
Linz, , Austria
Klinikum Kreuzschwestern Wels
Wels, , Austria
Acibadem City clinic Tokuda hospital
Sofia, , Bulgaria
UMHAT Aleksandrovska
Sofia, , Bulgaria
University Multi-Profile Hospital for Active Treatment (UMHAT) St. Ivan Rilski
Sofia, , Bulgaria
National Specialized Hospital for Active Treatment of Hematology Diseases
Sofia, , Bulgaria
UMHAT SofiaMed
Sofia, , Bulgaria
University Hospital Prof. Dr. Stoyan Kirkovich AD
Stara Zagora, , Bulgaria
Beijing YouYi Hospital-Beijing Friendship Hospital Capital Medical University
Beijing, , China
Peking University Third Hospital
Beijing, , China
The First Affiliated Hospital Of Bengbu Medical College
Bengbu, , China
The Affiliated Hospital of Chengde Medical University
Chengde, , China
The Affiliated Hospital of Inner Mongolia Medical University
Hohhot, , China
The Affiliated Huaian No.1 People's Hospital of Nanjing Medical University
Huai'an, , China
Huizhou Central People's Hospital
Huizhou, , China
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
Tianjin, , China
Union Hospital Tongji Medical College of Huazhong University of Science and Technology (HUST)
Wuhan, , China
Wuxi People's Hospital (Wuxi No.1 People's Hospital)
Wuxi, , China
Affiliated Hospital of Jiangsu University
Zhenjiang, , China
University Hospital Center Zagreb
Zagreb, , Croatia
Fakultni Nemocnice Ostrava
Ostrava, , Czechia
Fakultni nemocnice Kralovske Vinohrady
Prague, , Czechia
CHU d'Amiens-Picardie - Hopital SUD
Amiens, , France
Centre Hospitalier Universitaire (CHU) - Hopital Henri Mondor
Créteil, , France
Centre Hospitalier Universitaire Dijon Bourgogne Medecine Interne et Immunologie Clinique
Dijon, , France
University Hospital Carl Gustav Carus
Dresden, , Germany
Universitaetsklinikum Essen (AoR)
Essen, , Germany
Semmelweis University-Internal Medicine and Haematology
Budapest, , Hungary
Gyor-Moson-Sopron Varmegyei Petz Aladar Egyetemi Oktato Korhaz
Győr, , Hungary
Mater Misericordiae University Hospital
Dublin, , Ireland
St James's Hospital - Cancer Clinical Trials Office
Dublin, , Ireland
Azienda ULSS 7 Pedemontana
Bassano del Grappa, , Italy
Universita Degli Studi Di Firenze - Azienda Ospedaliero-Universitaria Careggi (AOUC)
Florence, , Italy
Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico
Milan, , Italy
Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico
Milan, , Italy
ASST Grande Ospedale Metropolitano Niguarda
Milan, , Italy
AO Maggiore Della Carita
Novara, , Italy
U.O.C. Ematologia Ospedale Santa Maria delle Croci
Ravenna, , Italy
Arcispedale Santa Maria Nuova (ASMN) Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS)
Reggio Emilia, , Italy
A.O.U. Citta della Salute e della Scienza di Torino
Torino, , Italy
AO Ordine Mauriziano di Torino
Torino, , Italy
Azienda Sanitaria Universitaria Integrata
Trieste, , Italy
ASST Sette Laghi Ospedale di circolo e Fondazione Macchi
Varese, , Italy
Szpital Uniwersytecki nr 2 im. Dr Jana Biziela w Bydgoszczy
Bydgoszcz, , Poland
Pratia Onkologia Katowice
Katowice, , Poland
Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. M. Kopernika w Lodzi
Lodz, , Poland
NZOZ Neuromed M. i M. Nastaj Sp.P.
Lublin, , Poland
Uniwersytecki Szpital Kliniczny Nr 4 w Lublinie Centrum Innowacyjnych Terapii
Lublin, , Poland
Szpital Specjalistyczny im. Jedrzeja Sniadeckiego w Nowym Saczu
Nowy Sącz, , Poland
Wojewodzki Szpital Zespolony im. Ludwika Rydygiera w Toruniu
Torun, , Poland
Unidade Local de Saude de Braga
Braga, , Portugal
Unidade Local de Saude Gaia e Espinho, E.P.E.
Vila Nova de Gaia, , Portugal
Spitalul Clinic Coltea, Clinica de Hematologie
Bucharest, , Romania
Spitalul Clinic Colentina
Bucharest, , Romania
Spitalul Clinic Judetean de Urgenta Sibiu (SCJS) (Clinical County Hospital Sibiu)
Sibiu, , Romania
Spitalul Clinic Judetean de Urgenta Targu-Mures
Târgu Mureş, , Romania
Clinical Center of Serbia
Belgrade, , Serbia
University Clinical Centre of Kragujevac
Kragujevac, , Serbia
Clinical Center of Nis
Niš, , Serbia
University Clinical Hospital Center Zemun
Zemun, , Serbia
General Hospital Djordje Joanovic
Zrenjanin, , Serbia
Complejo Hospitalario Universitario A Coruna
A Coruña, , Spain
Instituto Catalan de Oncologia - Hospital Duran i Reynals
L'Hospitalet de Llobregat, , Spain
Hospital Universitario Ramon y Cajal
Madrid, , Spain
Hospital General Universitario Morales Meseguer
Murcia, , Spain
University Hospital Quironsalud Madrid
Pozuelo de Alarcón, , Spain
Hospital Clinico Universitario - University of Valencia
Valencia, , Spain
Queen Elizabeth Hospital Birmingham - University Hospitals Birmingham NHS Foundation Trust
Birmingham, , United Kingdom
Bradford Royal Infirmary - Bradford Teaching Hospitals NHS Foundation
Bradford, , United Kingdom
University Hospitals Coventry and Warwickshire NHS Trust
Coventry, , United Kingdom
Glasgow Royal Infirmary - North Glasgow University Hospital Division
Glasgow, , United Kingdom
University Hospitals of Leicester NHS Trust-Leicester Royal Infirmary
Leicester, , United Kingdom
Barts and the London Pathology & Pharmacy Building - Barts Health NHS Trust
London, , United Kingdom
Hammersmith Hospital, Imperial College School Of Medicine - Imperial College Healthcare NHS Trust
London, , United Kingdom
Royal Cornwall Hospital (RCH)
Truro, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Role: backup
Role: backup
Role: backup
Role: backup
Role: backup
Role: backup
Role: backup
Role: backup
Role: backup
Role: backup
Role: backup
Role: backup
Role: backup
Role: backup
Role: backup
Role: backup
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2024-515451-38-00
Identifier Type: CTIS
Identifier Source: secondary_id
ARGX-113-2402
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.